

Price Perf. (1m/3m) (%)



NUF OM . OMR (RHS)

Liva Group (LIVA) - FY23 Result Review

Analyst: Neetika Gupta **Accumulate** Target Price (OMR): 0.380 Previous Recommendation: TP: OMR 0.380 per share; Accumulate 11-October-2023 Upside / (Downside): Previous Reco. & Date: 13.4% 3/5/2024 Date: LIVA OM Bloomberg Ticker Current Market Price (OMR) 0.335 60 52wk High / Low (OMR) 0.35/0.335 50 0.350 12m Average Vol. (000) 0.3 40 0.345 Mkt. Cap. (USD/OMR mn) 347/133 Shares Outstanding (mn) 398.4 30 0.340 Free Float (%) 57% 20 0.335 3m Avg Daily Turnover (000) 0.1 6m Avg Daily Turnover (000) 0.2 10 0.330 P/E'24e (x) 28.1 0.325 Aug-23 Sep-23 Jun-23 Dec-23 P/Bv'24e(x) 1.2 Dividend Yield '24 (%)

Volume, '000 (LHS)

Insurance revenue increased by 43% during FY23

For FY23, the company's insurance revenue increased by 43% YoY to OMR 310.8mn, primarily due to the consolidation of businesses throughout the year, thereby expanding geographical footprint and product coverage. The notable performance observed in personal lines primarily attributed to the sustained effectiveness of the KSA growth strategy introduced in 2020, coupled with the adaptations against the regulatory adjustments that have facilitated expansion within the motor insurance market. Furthermore, the Health & Life segment demonstrated considerable growth, particularly in the UAE, driven by heightened demand for medical products, thereby achieving enhanced scalability. The insurance service result grew 65% YoY to OMR 9.0mn, the underwriting revenue was impacted by the external market factors such as higher claims frequency and severity across various markets and business lines.

Investment income increased by 90%, in line with our expectations

For FY23, the total investment income grew ~90% YoY to OMR 12.9mn in line our expectations, driven by an increase in top-line growth and portfolio optimization with a more aggressive investment strategy in the KSA portfolio. The result was supported by a small amount of amortization write offs and the sale of a property in the UAE, as part of the post-merger property rationalization strategy. As a result of strong investment income, the company managed to register YoY net profit growth of 107% to reach OMR 6.4mn.

Maintain our recommendation on the stock

Overall, Liva group performed well in FY23 and is aligning its growth strategy across core markets, with enhanced technical resilience across Personal and Commercial lines. To improve profitability, the company is focused on achieving portfolio rebalancing and the book optimization. Moreover, the healthcare industry in the GCC region is undergoing a phase of growth and transformation as healthcare reforms aim to meet the increasing demands for health services and enhance health standards in the region. A mandatory health insurance in Oman is expected to commence in 2024, covering employees, their dependents, tourists and foreign visitors. As the home market for the Liva, the group plans to capitalize on the increased addressable market, with the expectation of a full roll out of the scheme in late 2024 or early 2025. Accordingly, we continue to maintain Accumulate rating on stock with the previous target price of OMR 0.380.

LIVA is trading at 2024e P/E of 28.5x, representing a 4% discount compared to the historical average P/E of 29.7x. Additionally, P/Bv multiple of 1.14x, based on our FY23 estimate, represents a 7% discount compared to the historical average P/Bv of 1.2x.

Income Statement					
(OMR mn)	FY22	FY23	FY23e	YoY	Var
Insurance Revenue	217.0	310.8		43%	
Insurance Service Result	5.5	9.0		65%	
Total Investment Income	6.8	12.9	12.1	90%	6.4%
Profit Before Tax	4.0	7.5		87%	
Income Tax expense	(0.9)	(1.1)			
Profit After Tax	3.1	6.4		107%	
Equity attributable to shareholders	100.3	107.2			
of the parent	100.3	107.2			
Source: Company Reports, MSX, U Capital Research					

For our previous report, please click here





Investment Research

Ubhar-Research@u-capital.net

Head of Research

Neetika Gupta

+968 2494 9036

neetika@u-capital.net

Research Team

Ahlam Al-Harthi

+968 2494 9024

ahlam.harthi@u-capital.net

Said Ghawas

+968 2494 9034

said.ghawas@u-capital.net

Amira Al Alawi

+968 2494 9112

amira.alalawi@u-capital.net

Head of Brokerage

Talal Al Balushi

+968 2494 9051

talal@u-capital.net

Visit us at: www.u-capital.net







Disclaimer

Recommendation			
BUY	Greater than 20%		
ACCUMULATE	Between +10% and +20%		
HOLD	Between +10% and -10%		
REDUCE	Between -10% and -20%		
SELL	Lower than -20%		



Ubhar Capital SAOC (U Capital)

Website: www.u-capital.net
PO Box 1137
PC 111, Sultanate of Oman
Tel: +968 2494 9036
Fax: +968 2494 9099

Email: research@u-capital.net

Disclaimer: This report has been prepared by Ubhar Capital (U Capital) Research and is provided for information purposes only. Under no circumstances is it to be used or considered as an offer to sell or solicitation of any offer to buy. While all reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. The company accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. All opinions and estimates included in this document constitute U Capital Research team's judgment as at the date of production of this report and are subject to change without notice. This report may not be reproduced, distributed or published by any recipient for any other purpose.